ReviewFrontiers in pharmacology2022
Recent Advances in Chitosan and its Derivatives in Cancer Treatment.
Review in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 1 synthesis or guideline pooled it, 114 citations in OpenAlex.
- Integrating AI with Biosensors and Voltammetry for Neurotransmitter Detection and Quantification: A Systematic Review.Biosensors · 2025Pooled it
- Mitochondria-Targeted Nanotherapies in Aging Neurodegenerative Disorders: Emerging Prospects and Clinical Potential.Advanced healthcare materials · 2026Review
- In vitro cytotoxic and apoptotic effects of chitosan-coated gold nanoparticles on HT-29 human colorectal adenocarcinoma cells.BMC gastroenterology · 2026Article
- Rewiring mTOR signaling in Alzheimer's disease: emerging mTOR modulators beyond oncology.Bioscience reports · 2026Review
- Effect of fungal chitosan on the morphology, biochemical, and genetic changes in selected genotypes of Scutellaria barbata D. Don under in vitro conditions.Scientific reports · 2026Article
- Targeted nanocomposite delivery system of amygdalin using chitosan/reduced graphene oxide-zinc oxide/hyaluronic acid for treatment of head and neck squamous cell carcinoma.BMC oral health · 2026Article
- Multifunctional chitosan-doxorubicin nanocarriers: advancing targeted breast cancer chemotherapy.Molecular cancer · 2026Review
- Applications of Chitosan, an Eco-Friendly Biopolymer in Agricultural Systems, Herbal Products, and Functional Foods: A Review.Food science & nutrition · 2026Article
- Natural carrier systems in cancer vaccines and immunotherapy.Human vaccines & immunotherapeutics · 2025Review
- Effect of pyrogallol nanocomposite on miRNA and its associated pathways during radiation-induced toxicity in small intestine of irradiated Balb/C mice.Medical oncology (Northwood, London, England) · 2025Article
- Chitosan-based formulations for therapeutic applications. A recent overview.Journal of biomedical science · 2025Review
- Exploring the synergistic effects of metformin and doxorubicin loaded chitosan nanoparticles for A549 lung cancer therapy.Scientific reports · 2025Article
- Functionalized chitosan as nano-delivery platform for CRISPR-Cas9 in cancer treatment.Asian journal of pharmaceutical sciences · 2025Review
- Carbon nanotubes/ordered mesoporous carbon/chitosan nanocomposite as a promising carrier for everolimus targeted delivery toward lung cancer cells.Journal of materials science. Materials in medicine · 2025Article
- Effect of chitosan nanoparticles conjugated with the cell free supernatant of Bifidobacterium bifidum on the expression of genes related to colorectal cancer in colon adenocarcinoma (Caco-2) cell line.BMC gastroenterology · 2025Article
- Chitosan Biomaterials: Advances and Challenges-2nd Edition.International journal of molecular sciences · 2025Article
- Alginate and chitosan-coated ferulic acid-loaded selenium nanoparticles: synthesis, characterization, and anticancer activity against MDA-MB-231 breast cancer cells.Medical oncology (Northwood, London, England) · 2025Article
- Article
- Studying the impact of chitosan salicylaldehyde/schiff base/CuFeScientific reports · 2025Article
- Nanoparticle-Mediated Cuproptosis and Photodynamic Synergistic Strategy: A Novel Horizon for Cancer Therapy.Cancer medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer has become a main public health issue globally. The conventional treatment measures for cancer include surgery, radiotherapy and chemotherapy. Among the various available treatment measures, chemotherapy is still one of the most important treatments for most cancer patients. However, chemotherapy for most cancers still faces many problems associated with a lot of adverse effects, which limit its therapeutic potency, low survival quality and discount cancer prognosis. In order to decrease these side effects and improve treatment effectiveness and patient's compliance, more targeted treatments are needed. Sustainable and controlled deliveries of drugs with controllable toxicities are expected to address these hurdles. Chitosan is the second most abundant natural polysaccharide, which has excellent biocompatibility and notable antitumor activity. Its biodegradability, biocompatibility, biodistribution, nontoxicity and immunogenicity free have made chitosan become a widely used polymer in the pharmacology, especially in oncotherapy. Here, we make a brief review of the main achievements in chitosan and its derivatives in pharmacology with a special focus on their agents delivery applications, immunomodulation, signal pathway modulation and antitumor activity to highlight their role in cancer treatment. Despite a large number of successful studies, the commercialization of chitosan copolymers is still a big challenge. The further development of polymerization technology may satisfy the unmet medical needs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.